Specifically, teglarinad (GMX1777) exhibited the highest total score when docked by the EPAS1 protein, and it was found that higher EPAS1 expression correlated with higher sensitivity of teglarinad to treat HCC cells. The gene discussed is EPAS1; the disease is hepatocellular carcinoma.